Physician profile
Parul Sarwal
NPI 1740767425
$1,860.69
in general payments reported to CMS, 2019-2025
25 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $465 · 2021: $126 · 2022: $166 · 2023: $400 · 2024: $239 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $310.99 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $288.73 | 2019-2024 | Xarelto |
| Abbvie INC. | $230.53 | 2020-2024 | Dalvance |
| Astrazeneca Pharmaceuticals LP | $214.60 | 2019-2025 | Airsupra |
| Alexion Pharmaceuticals, INC. | $115.55 | 2020-2023 | Ultomiris |
| Allergan, INC. | $100.56 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $78.48 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.02 | 2019-2022 | |
| Glaxosmithkline, LLC. | $48.70 | 2020-2025 | Nucala |
| Gilead Sciences, INC. | $43.58 | 2020 | |
| Neurelis, INC. | $42.66 | 2023 | Valtoco |
| Novo Nordisk INC | $41.68 | 2024 | Ozempic, Rybelsus |
| Grifols USA, LLC | $32.01 | 2023 | Gamunex-C |
| Lexicon Pharmaceuticals, INC. | $29.78 | 2024 | Inpefa |
| Inari Medical, INC. | $29.49 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $27.17 | 2024 | Opsumit |
| Otsuka America Pharmaceutical, INC. | $23.07 | 2019 | |
| Biomerieux INC | $22.14 | 2023 | |
| Viiv Healthcare Company | $20.97 | 2019 | |
| Biogen, INC. | $20.74 | 2019 | |
| Janssen Scientific Affairs, LLC | $20.30 | 2023 | Xarelto |
| Scpharmaceuticals INC. | $19.10 | 2025 | |
| Jazz Pharmaceuticals INC. | $18.92 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.45 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parul Sarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.